| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2006.06.9039 |
| P698 | PubMed publication ID | 16943526 |
| P50 | author | Aimery de Gramont | Q38294926 |
| Isabelle Tabah-Fisch | Q38295619 | ||
| Daniel J. Sargent | Q43055483 | ||
| P2093 | author name string | Richard M Goldberg | |
| Christophe Tournigand | |||
| Erin Green | |||
| Thierry Andre | |||
| Mace L Rothenberg | |||
| Harry Bleiberg | |||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| oxaliplatin | Q422327 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 4085-4091 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer | |
| P478 | volume | 24 |
| Q43585352 | A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man. |
| Q43000487 | A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect. |
| Q89414205 | A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies |
| Q36778075 | A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). |
| Q37149148 | Accomplishments in 2007 in the treatment of advanced colorectal cancer |
| Q34488296 | Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis |
| Q92012575 | Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study |
| Q37574640 | Adjuvant chemotherapy for stages II, III and IV of colon cancer |
| Q46530440 | Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. |
| Q61868117 | Adjuvant chemotherapy of colorectal cancer |
| Q34725978 | Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. |
| Q37956401 | Adjuvant therapy for early colon cancer: current status |
| Q37965640 | Adjuvant therapy in colon cancer |
| Q50887433 | Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study |
| Q37580903 | Advances in the pharmacological treatment of gastro-oesophageal cancer |
| Q37169832 | Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma |
| Q27002538 | Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? |
| Q37229270 | Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy |
| Q36073427 | Assessing Compliance with National Comprehensive Cancer Network Guidelines for Elderly Patients with Stage III Colon Cancer: The Fox Chase Cancer Center Partners' Initiative |
| Q37467168 | Assessment of cancer care in Indian elderly cancer patients: A single center study |
| Q37644543 | Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study |
| Q86553009 | Association between chemotherapy and cognitive impairments in a large cohort of patients with colorectal cancer |
| Q42243044 | Balancing the efficacy and toxicity of chemotherapy in colorectal cancer |
| Q52657104 | Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis |
| Q35894352 | Biological, clinical, and psychosocial correlates at the interface of cancer and aging research |
| Q28069620 | Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example |
| Q35154728 | Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Rese |
| Q37598467 | Challenges in the Management of Older Patients With Colon Cancer |
| Q40114261 | Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location |
| Q49680114 | Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors |
| Q43259379 | Chemotherapy of colorectal cancer |
| Q40666865 | Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer |
| Q41044367 | Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. |
| Q54719191 | Clinical predictive factors. |
| Q82817217 | Clinical study on survival benefit for elderly patients with resected stage Ⅱ or Ⅲ colorectal cancer based on traditional Chinese medicine syndromedifferentiation and treatment |
| Q37092129 | Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. |
| Q37709717 | Colorectal Cancer OncoGuia |
| Q37073448 | Colorectal cancer treatment in older patients. |
| Q36824698 | Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer |
| Q33387054 | Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems |
| Q33399154 | Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer |
| Q38901676 | Comparative effectiveness of chemotherapy vs resection of the primary tumour as the initial treatment in older patients with Stage IV colorectal cancer |
| Q30422446 | Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer |
| Q46042915 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study |
| Q30422095 | Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. |
| Q33397780 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer |
| Q85651019 | Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity |
| Q88061114 | Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer |
| Q92242538 | Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer |
| Q43006999 | Current medicinal treatment of metastasized colorectal carcinoma |
| Q37077225 | Current status of adjuvant therapy for colon cancer. |
| Q37771244 | Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. |
| Q37273366 | Decision making and quality of life in the treatment of cancer: a review. |
| Q30244769 | Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer |
| Q36874822 | Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients |
| Q45870223 | Do we need oncology trials tailored for the elderly or frail? |
| Q38534405 | Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q53043230 | Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer |
| Q50797877 | Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients |
| Q40888760 | Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease |
| Q50085723 | Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence |
| Q30418160 | Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years |
| Q37325560 | Effect of age on drug metabolism in women with breast cancer |
| Q41161751 | Effect of age on the development of chemotherapy-associated liver injury in colorectal cancer liver metastasis |
| Q33739583 | Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. |
| Q39831242 | Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. |
| Q42870892 | Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients |
| Q37845734 | Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis |
| Q38956434 | Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer |
| Q35130633 | Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry |
| Q96231793 | Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study |
| Q34458029 | Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study |
| Q36411962 | Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer |
| Q28486580 | Efficacy, compliance and reasons for refusal of postoperative chemotherapy for elderly patients with colorectal cancer: a retrospective chart review and telephone patient questionnaire |
| Q43474453 | Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study |
| Q35834442 | Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the O |
| Q46929599 | FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study |
| Q46448482 | FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients |
| Q48248858 | Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer. |
| Q35863869 | First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According toKRASStatus from a Spanish TTD Group Study |
| Q33383727 | Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 |
| Q37411495 | Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy |
| Q37910388 | From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer |
| Q35185110 | Gemcitabine in elderly patients with advanced pancreatic cancer |
| Q53823553 | General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force's position statement. |
| Q38565301 | Genetic markers of recurrence in colorectal cancer |
| Q36135372 | Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer |
| Q36416460 | How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study |
| Q27026516 | How to select the optimal treatment for first line metastatic colorectal cancer |
| Q43831814 | Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. |
| Q36977050 | Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database |
| Q36920315 | Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials |
| Q43510488 | Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands |
| Q41735144 | Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009. |
| Q33384357 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer |
| Q27853363 | KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer |
| Q45719835 | Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years |
| Q34048515 | Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics |
| Q40738457 | Liver Metastasis from Colorectal Cancer in the Elderly: Is Surgery Justified? |
| Q64257150 | Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy |
| Q37466459 | Longitudinal patterns of chemotherapy use in metastatic colorectal cancer |
| Q85746996 | Low-toxicity treatment for colorectal cancer in elderly people |
| Q41056015 | Lower body mass index predicts worse cancer-specific prognosis in octogenarians with colorectal cancer |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q26822600 | Managing Choices for Older Patients with Colon Cancer: Adjuvant Therapy |
| Q41517741 | Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter? |
| Q38032558 | Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review). |
| Q37948702 | Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly |
| Q37318017 | Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients |
| Q34050521 | NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. |
| Q37301707 | North Central Cancer Treatment Group--achievements and perspectives |
| Q84592690 | Ongoing Challenge of Stage II Colon Cancer |
| Q35851378 | Optimizing surgical care of colon cancer in the older adult population |
| Q64110215 | Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials |
| Q39803653 | Oxaliplatin-Induced Neuropathy in Colorectal Cancer |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q37584933 | Oxaliplatin-related neuropathy in Indian patients - no difference between generic and original molecules |
| Q37965616 | Oxaliplatin: a review of approved uses. |
| Q35902810 | Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 |
| Q36169867 | Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience |
| Q36989058 | Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older |
| Q48395650 | Palliative chemotherapy in elderly patients with metastatic colorectal cancer: do we know how it should be used? |
| Q36715263 | Pharmacokinetics of chemotherapy in the older patient. |
| Q41559464 | Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. |
| Q53476543 | Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. |
| Q37623740 | Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. |
| Q33414068 | Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer |
| Q30744596 | Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007 |
| Q57224370 | Practical Outcome of Adjuvant FOLFOX4 Chemotherapy in Elderly Patients with Stage III Colon Cancer: Single-center Study in Korea |
| Q38767373 | Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis |
| Q36954147 | Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. |
| Q44706440 | Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. |
| Q33778129 | Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen |
| Q64913937 | Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. |
| Q83637470 | Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma |
| Q40407871 | Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). |
| Q40002771 | ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy |
| Q89208465 | Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population |
| Q80531122 | Rectal cancer surgery in the elderly: analysis of consecutive 158 patients with stage III rectal cancer |
| Q40586852 | Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy |
| Q33405177 | Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. |
| Q35076279 | Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects |
| Q37708010 | Role of cetuximab in first-line treatment of metastatic colorectal cancer |
| Q37113563 | Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer |
| Q37820653 | Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer |
| Q37242523 | Safety and Effectiveness of Oxaliplatin-Based Chemotherapy Regimens in Adults 75 Years and Older With Colorectal Cancer |
| Q33928825 | Senior Adult Oncology: Three Cases of Advanced Cancer in Patients of Advanced Age |
| Q47119173 | Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status |
| Q26765344 | Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II |
| Q37387981 | Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression |
| Q38627295 | Synchronous colorectal liver metastases: focus on the elderly : An Effectiveness Study from Routine Care. |
| Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
| Q38059634 | Systemic Treatment of Gastrointestinal Cancer in Elderly Patients |
| Q34982764 | Systemic therapy for elderly patients with gastrointestinal cancer. |
| Q38961110 | Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. |
| Q37954162 | Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients |
| Q34339987 | The Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colorectal Cancer is Independent of Age and Comorbidity |
| Q34773758 | The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials |
| Q37962058 | The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer |
| Q36975003 | The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer |
| Q36895084 | The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients |
| Q41231669 | The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients |
| Q34686967 | The impact of low-grade toxicity in older people with cancer undergoing chemotherapy |
| Q45077543 | The impact of medication therapy management in older oncology patients |
| Q27011366 | The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer |
| Q36715266 | Tolerance to chemotherapy in elderly patients with cancer |
| Q43541378 | Treatment and complications in elderly stage III colon cancer patients in the Netherlands |
| Q35234803 | Treatment considerations in elderly colorectal cancer patients. |
| Q37225720 | Treatment in advanced colorectal cancer: what, when and how? |
| Q55424174 | Treatment of Elderly Patients with Colorectal Cancer. |
| Q37910392 | Treatment of Metastatic Colorectal Cancer |
| Q38050375 | Treatment of colorectal cancer in older patients |
| Q37612945 | Treatment of metastatic colorectal cancer in the elderly |
| Q37298994 | Treatment of the elderly colorectal cancer patient: SIOG expert recommendations |
| Q80455371 | Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer |
| Q45356332 | Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN). |
| Q37153314 | Which strategies will lead to progress in the management of colorectal cancer? |
| Q84745075 | [Can the results of clinical trials of pharmacological interventions be transferred into everyday clinical practice?] |
Search more.